

R⁶ is aminosulfonyl;

R⁷ and R⁸ are independently selected from H and halogen;


R⁹ is C₁₋₆-alkyl, C₁₋₆-alkoxy or halogen;

m,n, p and q are 1;

5 or pharmaceutically acceptable salts.

3. A compound according to claim 1 or 2, wherein R¹ is substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substituted pyridinyl and substituted
10 pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵.
4. A compound according to any one of claims 1 to 3, wherein R¹ is substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substituted pyridinyl and substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵.
5. A compound according to any one of claims 1 to 4, wherein Y is -C(O)-.
- 15 6. A compound according to any one of claims 1 to 2, wherein R² is substituted phenyl or substituted pyridinyl, wherein substituted phenyl and substituted pyridinyl are substituted by R⁶, R⁷ and R⁸.
7. A compound according to any one of claims 1 to 6, wherein R³ is halo-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonylamino or tetrahydropyranyl-C₁₋₆-alkoxy.
- 20 8. A compound according to any one of claims 1 to 7, wherein R³ is tetrahydropyranyl-C₁₋₆-alkoxy.
9. A compound according to any one of claims 1 to 8, wherein R⁴ is H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl.
10. A compound according to any one of claims 1 to 9, wherein R⁴ is C₃₋₈-cycloalkyl.
- 25 11. A compound according to any one of claims 1 to 10, wherein R⁵ is H.

12. A compound according to any one of claims 1 to 11, wherein R^7 and R^8 are independently selected from H and halogen.
13. A compound according to any one of claims 1 to 12, wherein R^7 is H or halogen.
14. A compound according to any one of claims 1 to 13, wherein R^8 is H.
- 5 15. A compound according to any one of claims 1 to 13, wherein R^9 is halogen or C_{1-6} -alkoxy.
16. A compound according to any one of claims 1 to 15, wherein m, n, p and q are 1.
17. A compound according to any one of claims 1 to 16, wherein
 - R^1 is substituted pyridinyl or substituted pyridinyl- C_{1-6} -alkyl, wherein substituted pyridinyl and substituted pyridinyl- C_{1-6} -alkyl are substituted by R^3 , R^4 and R^5 ;
 - 10 Y is -C(O)-;
 - W is -C(O)-;
 - R^2 is substituted phenyl or substituted pyridinyl, wherein substituted phenyl and substituted pyridinyl are substituted by R^6 , R^7 and R^8 ;
 - R^3 is tetrahydropyranyl- C_{1-6} -alkoxy;
 - 15 R^4 is C_{3-8} -cycloalkyl;
 - R^5 is H;
 - R^6 is aminosulfonyl;
 - R^7 is H or halogen;
 - R^8 is H;
 - 20 R^9 is halogen or C_{1-6} -alkoxy;
 - m, n, p and q are 1
 - or pharmaceutically acceptable salts.
18. A compound according to claim 1 and of formula I(a),



wherein

R¹ is substituted pyridinyl or substituted pyridinyl-C₁₋₆-alkyl, wherein substituted pyridinyl and substituted pyridinyl-C₁₋₆-alkyl are substituted by R³, R⁴ and R⁵;

5 Y is -C(O)-;

W is -C(O)-;

R² is substituted phenyl or substituted pyridinyl, wherein substituted phenyl and substituted pyridinyl are substituted by R⁶, R⁷ and R⁸;

R³ is tetrahydropyranyl-C₁₋₆-alkoxy;

10 R⁴ is C₃₋₈-cycloalkyl;

R⁵ is H;

R⁷ is H or halogen;

R⁸ is H;

R⁹ is halogen or C₁₋₆-alkoxy;

15 m, n, p and q are 1

or pharmaceutically acceptable salts.

20. A compound according to any one of claims 1 to 19, selected from

trans-5-(2-fluoro-4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl ester;

20

trans-4-[3a-fluoro-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-fluorobenzenesulfonamide;

(+)-(3aR,6aR)-3a-methyl-5-(4-sulfamoyl-benzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

5 (-)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester ;

(-)-trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester ;

10 (-)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl ester ;

(-)-(3aS,6aS)-3a-methyl-5-(4-sulfamoylbenzoyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

15 (+)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

(+)-trans-5-(4-sulfamoyl-benzoyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester ;

20 (+)-trans-5-(4-sulfamoyl-benzoyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 3-(2,2-dimethyl-propionylamino)-5-trifluoromethyl-pyridin-2-ylmethyl ester;

and pharmaceutically acceptable salts thereof.

21. A compound according to any one of claims 1 to 20, selected from


trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;

25 trans-6-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]pyridine-3-sulfonamide;

trans-4-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-fluoro-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-fluorobenzenesulfonamide;

and pharmaceutically acceptable salts thereof.

22. A process to prepare a compound according to any one of claims 1 to 21 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III), wherein R^1 , R^2 , R^9 , m , n , p and q are as defined in any one of claim 1 to 21 and W is -C(O)-.



23. A compound according to any one of claims 1 to 21 for use as therapeutically active substance.
24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21 and a therapeutically inert carrier.
25. A compound according to any one of claims 1 to 21 for the treatment or prophylaxis of ocular conditions.
26. The use of a compound according to any one of claims 1 to 21 for the preparation of a medicament for the treatment or prophylaxis of ocular conditions.